Engflag

Sofgen

Quick links to important sections

Sofgen

Sofgen_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sofgen

Property Description
Active Ingredient Sofosbuvir (INN)
Form Film-coated tablet (oral route)
Pharmacological Class Direct-Acting Antiviral (DAA)
General Purpose Foundational component for managing Chronic Hepatitis C infection
Origin Synthetic compound (Nucleotide Analog prodrug)

What is Sofgen and Its Pharmacological Identity?

Sofgen is a prescription-only medicine defined by its core active substance, Sofosbuvir. This drug belongs to the specialized pharmacological class of Direct-Acting Antivirals (DAAs), which represents a highly targeted approach to managing persistent viral diseases.

The medication's designation as a DAA is clinically recognized for its high specificity and efficacy against the target virus, which distinguishes it from older, less-targeted therapies. Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor. It is used as a foundational single-ingredient product within broader combination therapy regimens to maximize efficacy.

Sofosbuvir Composition: Origin and Pharmaceutical Form

The active ingredient Sofosbuvir is a synthetic compound that functions as a Nucleotide Analog prodrug. The term prodrug signifies that the chemical is chemically engineered to be inactive upon oral administration and must be metabolized inside the body's cells to become the fully active therapeutic agent. Sofgen is typically supplied as a film-coated tablet, a solid dosage form designed for stability and patient compliance, and allows for once-daily administration.

The chemical structure of Sofosbuvir is a unique phosphoramidate designed to mimic the natural building blocks of the virus’s genetic material. This specific chemical architecture is what grants the drug its highly focused action and contributes to its high barrier to resistance.

What is the General Therapeutic Purpose of Sofgen?

The general therapeutic purpose of Sofgen is to achieve potent activity against the target virus. The drug's mechanism is fundamentally focused on viral replication inhibition by disrupting a key enzyme the virus requires to multiply. This action provides critical support in managing Chronic Hepatitis C infection by substantially reducing the viral load, which is the primary goal of modern antiviral management.

What side effects are possible with Sofgen?

Possible Side Effects and Safety Information

The official safety profile of Sofgen (Sofosbuvir) is derived from its use as part of combination therapy regimens for Chronic Hepatitis C infection. Documented adverse reactions are classified by frequency based on findings from clinical studies.

Classification of Officially Documented Adverse Reactions

The most frequently observed adverse reactions, classified as very common (incidence 10%) in various combination regimens, include Fatigue, Headache, Nausea, and Insomnia. Effects classified as common (incidence 1% - <10%) can affect the gastrointestinal system (e.g., Diarrhoea) and the skin (Rash and Pruritus).

Serious Adverse Reactions and Safety Patterns

Regulatory authorities highlight critical safety concerns that have been reported with Sofosbuvir-containing regimens:

  • Severe Symptomatic Bradycardia and Heart Block: Cases of severe, symptomatic slow heart rate have been documented, especially when the regimen is co-administered with the drug Amiodarone. This reaction has been noted to generally occur within hours to days of starting the treatment.
  • Hepatitis B Virus (HBV) Reactivation: Patients co-infected with HBV and HCV are at risk of HBV reactivation during or after treatment with Direct-Acting Antivirals. This event can lead to serious liver complications, including hepatic failure.

Population-Specific Safety Considerations

Safety data is not fully established for certain patient groups. No dosage recommendation can be provided for individuals with severe renal impairment (estimated GFR <30 mL/min/1.73 m^2) or End Stage Renal Disease (ESRD) requiring dialysis. Furthermore, all patients must be tested for evidence of current or prior HBV infection before starting treatment to mitigate the risk of reactivation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the overdose profile of Sofgen primarily through its potential effects on the Central Nervous System (CNS) and the significant risk posed by co-ingestion with other substances.

Documented Overdose Presentations

Overdose manifestations can range in severity and may include:

  • Central Nervous System Effects: Agitation, confusion, delirium, seizures, and potentially coma.
  • Serotonin Syndrome: A life-threatening toxicity syndrome that may manifest with severe CNS symptoms and autonomic instability.
  • Cardiovascular Changes: Alterations in heart function, most commonly reported as tachycardia (rapid, irregular, or pounding heartbeat).
  • Gastrointestinal Distress: Nausea, vomiting, and diarrhea.

Critical Risk Factors and Emergency Action

While some instances of overdose with Sofgen alone may be relatively well-tolerated, toxicity is critically increased when the drug is taken in combination with other medications or alcohol. Co-ingestion is cited as a major factor that can escalate risk, leading to more severe outcomes, including the potential for a fatal reaction.

When to Seek Immediate Medical Help

Immediate emergency medical attention must be sought for any suspected overdose. The need for urgent care is especially critical if severe CNS effects (such as seizures or coma) are present, or if there is a known co-ingestion of other substances. Overdose management requires prompt medical evaluation and supportive care, including continuous monitoring of vital signs, cardiac function, and overall clinical status.

Therapeutic Uses of Sofgen

What Sofgen Treats: Main Uses and Benefits

Sofgen is utilized for its core function of providing symptomatic relief and supportive assistance, generally applied in contexts where additional symptomatic support is needed due to heightened or temporary distress. It is commonly used across conditions presenting with acute episodes characterized by periods of heightened symptoms.

Symptomatic management is a key therapeutic goal for drug classes used to manage symptoms related to physical discomfort. Sofgen helps address groups of symptoms that may appear suddenly or intensify over time, providing support that helps ease the overall symptom burden.

This medication plays a role in managing symptoms that interfere with daily functioning and create noticeable physiological strain. Its use is relevant for addressing distressing manifestations, easing challenging symptoms, and moderating pronounced symptoms.

“Sofgen is applied when appropriate during phases of increased distress or discomfort, supporting the patient's ability to cope more steadily with difficult episodes.”

It contributes to easing the overall symptom load during symptomatic periods and may assist with maintaining functional stability when symptoms escalate temporarily.

Quick Fact: Supports Symptom Clusters that become intense or disruptive.

Regulatory References

  1. NIH overview of Pain Management Medications

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Sofgen — Official Regulatory Information

Sofgen (sofosbuvir) is required to be used as part of a combination antiviral regimen for Chronic Hepatitis C infection, and monotherapy is not an approved use.

Eligibility Scope

Category Official Regulatory Classification
Populations for whom use is allowed Adults, older adults, and pediatric patients aged 3 years and older [FDA/EMA]. Patients with compensated cirrhosis (Child-Pugh A), and those with decompensated cirrhosis (Child-Pugh B or C) when used in specific approved regimens.
Populations for whom use is not recommended Lactation/Breastfeeding is generally not recommended as excretion into human milk is unknown [EMA SmPC].
Populations for whom use is contraindicated Patients with known hypersensitivity to the active substance or excipients. Patients taking strong P-gp inducers (e.g., rifampicin, St. John's Wort) due to risk of reduced effectiveness. Pregnant women and their male partners when Sofgen is prescribed with Ribavirin (due to Ribavirin's teratogenicity) [FDA Labeling].
Condition-specific eligibility rules Severe Renal Impairment (eGFR < 30 mL/ min/1.73 m^2) or End Stage Renal Disease (ESRD): No dosage recommendation can be made, limiting use in this patient population [FDA Labeling]. Co-infected Hepatitis B Virus (HBV) patients must be screened and monitored for potential HBV reactivation [FDA Boxed Warning].

Eligibility Classifications (High-Level)

Category Official Regulatory Wording
Eligibility severity classification Contraindicated (e.g., strong inducers). Not Established (e.g., pediatric patients < 3 years). No Dosage Recommendation (e.g., severe renal impairment/ESRD).
Eligibility-context constraints Must be used in Combination Therapy. Eligibility is dependent on the Co-administered drug's restrictions.

Connection to the overall eligibility profile

Official regulatory documents define patient eligibility by mandating Sofgen be used as a combination treatment, which applies the contraindications of other agents, such as Ribavirin's restriction for pregnant women. Use is further restricted by severe organ function limitations and the absence of established safety data for children under three years of age.

What should I know about interactions with other medicines?

The official regulatory interaction profile for a drug containing Sofosbuvir, which is often related to the trade name, is structured around specific pharmacokinetic and pharmacodynamic constraints.

Interaction Classifications and Restrictions

Interaction Classification Interacting Agents (Examples) Regulatory Constraint
P-gp/CYP Inducers Rifampin, Carbamazepine, Phenytoin, St. John's Wort Not Recommended/Contraindicated (Risk of reduced therapeutic effect)
Antiarrhythmics Amiodarone Not Recommended (Risk of serious symptomatic bradycardia)
Antacids/Gastric pH Modifiers Proton Pump Inhibitors (PPIs), H₂-receptor antagonists Use requires specific timing constraints or is Not Recommended

Official Interaction Statements

  • Contraindicated Combinations: Concomitant use with strong inducers of P-glycoprotein (P-gp) and/or moderate-to-potent Cytochrome P450 (CYP) enzymes is not recommended. This restriction is based on the risk that these agents will significantly decrease the drug's plasma concentrations, which may reduce its effectiveness.
  • Cardiovascular Caution: Co-administration with the antiarrhythmic amiodarone is officially not recommended due to the reported risk of severe symptomatic bradycardia. If this combination is medically necessary, enhanced cardiac monitoring is required.
  • Gastric Acidity Effects: Co-administration with drugs that increase gastric pH, such as Proton Pump Inhibitors (PPIs), is restricted as it may decrease the absorption and concentration of the drug. Specific administration timing relative to certain gastric acid reducers is required to maintain adequate exposure.
  • Anticoagulant and Diabetes Management: Clearance of the underlying viral infection may alter hepatic function, impacting the use of concomitant medications like warfarin or diabetic agents. Frequent monitoring of relevant laboratory parameters, such as INR and blood glucose levels, is required with potential dose adjustments of the co-administered medicines.

Mechanism of Action

Sofosbuvir is designed as an inactive compound (prodrug) that must be transformed by specific host-cell enzymes (kinases) inside the liver cells (hepatocytes) to create the potent, active species. This active species then acts as a competitive substrate that targets the NS5B RNA-dependent RNA polymerase, an enzyme required for viral replication.

The active drug species functions as a nucleotide analog, mimicking the virus's natural building blocks. When the viral enzyme attempts to copy its genetic material, it incorporates the analog into the growing viral RNA chain. This incorporation causes RNA chain termination, a molecular event that physically blocks the enzyme from extending the strand, which immediately halts the process of viral RNA synthesis.

The molecular arrest of viral replication at the cellular level translates into the primary physiological consequence. By preventing the synthesis of new genetic material, the mechanism fundamentally shuts down the pathogen's ability to multiply and produce new virions. The resulting physiological change is a reduction in the systemic viral load, which is the measurable biological effect of the mechanism.

Dosage and Administration Information

How to use Sofgen — Established Administration Guidelines

The usage of Sofgen (sofosbuvir) is defined by clinical documentation and is intended to be a fixed component of a wider antiviral treatment plan.

Administration Protocol

Instruction Component Established Guideline
Route of Administration The medicine is administered via the oral route only.
Standard Adult Dosing The established adult dose is 400 mg once daily. This dose is non-adjustable for patients with typical renal function.
Timing in Relation to Meals The film-coated tablet may be taken with or without food.
Preparation Requirements Tablets must be swallowed whole. To maintain the integrity of the medication and ensure proper delivery of the active substance, the tablet must not be chewed or crushed.

Procedural Context and Constraints

Sofgen must always be used in combination with other specified antiviral medicinal products; its use as a monotherapy is not recommended. The overall treatment duration is highly specific, most commonly established as 12 weeks or, for certain patient populations, 24 weeks, defining a finite course of use.

Dosing is standardized for most patients, but guidance is provided for specific populations. For instance, pediatric dosing is calculated based on body weight. Furthermore, it is documented that no dose recommendation can be given for patients presenting with severe renal impairment (eGFR < 30 mL/min/1.73m²), which establishes a constraint on its use in this population. If a dose is missed, it should be taken immediately if it is within 18 hours of the usual time; otherwise, the missed dose should be skipped entirely.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sofgen

This section provides a summary of the types of research and studies that have explored the use of Sofgen (Sofosbuvir) when applied as a foundational component in combination treatments for Hepatitis C Virus (HCV) infection. This overview is based on official regulatory and scientific literature and does not offer clinical advice.

Evidence for Use in Chronic Hepatitis C Virus (HCV) Infection

Research for chronic HCV infection was conducted in numerous Randomized Controlled Trials (RCTs). These trials were used in research exploring how viral activity changes over time and to examine outcomes of sofosbuvir-based regimens compared to older treatments or other combinations.

Studies monitored a key measurement called the Sustained Virologic Response 12 weeks post-treatment (SVR12), a biomarker defined as an undetectable level of the virus in the blood at 12 weeks after the end of therapy. These trials included adults who were either new to treatment (treatment-naïve) or had failed previous therapies (treatment-experienced), covering individuals across all major HCV genotypes (Genotypes 1 through 6). Findings describe patterns observed in these studies, with SVR12 measurements reported across various combinations and patient groups.

What remains uncertain is the full extent of the long-term changes, as follow-up durations were limited in the initial registration trials. While studies report specific rates of SVR12 in many standard populations, there is limited information for long-term outcomes, such as reduced risk of liver cancer or overall survival years after treatment.

Evidence in Acute and Recurrent HCV Infection Scenarios

The research for acute or recently acquired HCV infection is derived from a different type of evidence compared to chronic disease. Studies exploring this scenario often include smaller, prospective, single-arm studies and some dedicated RCTs that examined outcomes related to short-term symptom changes. These studies were used in research exploring short-term symptom changes and examined viral clearance following shorter treatment durations (e.g., 8 weeks).

Evidence related to HCV recurrence following a liver transplantation is also more specialized. This evidence is primarily derived from observational studies, retrospective analyses, and smaller patient cohorts due to the specific, complex nature of the population. These studies monitored outcomes related to the viral status of the new organ, with findings describing group patterns under those unique research conditions.

Studies in Specific Patient Populations

Dedicated research has examined the use of sofosbuvir-based regimens in specific patient populations that were sometimes excluded from the main pivotal trials. For example, specific trials were conducted in individuals co-infected with HIV-1. Research examined how viral response patterns were observed in this group, and findings indicate group patterns that were comparable to those of patients who only had HCV.

Key Studies & References

  1. AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection (HCV Guidance)

Frequently Asked Questions (FAQ)

Common questions about Sofgen (FAQ)

Q: Do I need a special prescription for Sofgen?

A: Sofgen is officially classified as a prescription-only medicine. It is required to be prescribed by a licensed healthcare professional as part of a specialized treatment plan.

Q: What are the general expectations for someone starting Sofgen therapy?

A: General expectations involve starting a fixed-duration combination treatment, which is typically 12 or 24 weeks. The primary goal of the treatment, based on clinical studies, is the achievement of a sustained viral response, defined as an undetectable viral load, while acknowledging the potential for common effects like fatigue or headache.

Q: How quickly does Sofgen start to work after taking it?

A: Official information indicates that the drug’s active substance is designed to be rapidly processed in the body after administration. The initial substance reaches peak levels in the body relatively quickly, generally within a few hours of administration.

Q: What is the typical timeframe for seeing the full effects of Sofgen?

A: The effectiveness of the treatment is measured using a standard benchmark called the Sustained Virologic Response (SVR). This response is officially measured 12 weeks after the conclusion of the fixed course of therapy.

Q: How long does the effect of Sofgen last in the body?

A: The key substances related to the drug remain detectable in the body for a certain period. According to regulatory data, one major component has an elimination half-life of approximately 27 hours.

Q: Can Sofgen be used by people who are pregnant?

A: Currently, there are no established safety data for the use of Sofgen alone during pregnancy, and regulatory authorities generally recommend avoiding its use as a precaution. The combination regimen including Ribavirin carries a specific contraindication (a regulatory restriction) for use during pregnancy.

Q: Do I need to change my diet while taking Sofgen?

A: According to the official administration guidelines, the film-coated tablet may be taken with or without food. No specific dietary changes are required for the use of this medicine.

Q: Are there different strengths or dosages of Sofgen available?

A: The drug is available as a 400 mg film-coated tablet for adult dosing. For children, the appropriate dosage is determined by body weight, and smaller tablets (such as 200 mg) or oral pellet formulations may be used.

Q: Why is Sofgen sometimes used with other medications?

A: Regulatory documents state that Sofgen must always be used as part of a combination regimen, as using it alone is not recommended. This combination approach is used to achieve the highest possible therapeutic activity and help reduce the risk of the virus developing resistance.

Q: Why do some people need to take Sofgen for a long time?

A: The standard duration of therapy is typically 12 weeks. However, official dosing regimens specify that some individuals—such as those with certain viral genotypes or those who are treatment-experienced—may be prescribed a longer treatment course of up to 24 weeks.

Q: What if I'm already taking multiple different medications, can I still take Sofgen?

A: The official product information lists several specific drug combinations that are either not recommended or contraindicated. A complete review of all concurrent medications is necessary because of the potential for interactions.

Q: Does Sofgen interact with common pain relievers like ibuprofen?

A: Regulatory data, based on how the body processes the drug, indicates that a clinically significant interaction with most common non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen is considered unlikely.

Q: Can Sofgen be taken with high blood pressure medicines?

A: Official documents do not list a general restriction for most common blood pressure medicines. However, there is a specific caution and not recommended status regarding the co-administration of the antiarrhythmic drug Amiodarone due to a risk of severe, slow heart rate.

Q: Are there any common side effects people report online for Sofgen?

A: Studies indicate that the most frequently reported side effects, listed as 'very common,' are Fatigue, Headache, Nausea, Insomnia (trouble sleeping), and Pruritus (itching). These effects were reported in individuals who received the combination treatment regimen.

Q: Is it normal to feel tired when starting Sofgen?

A: Yes, official reports indicate that Fatigue is one of the most frequently observed side effects in clinical studies, categorized as a 'very common' effect of the combination regimen.

Q: Can Sofgen affect sleep patterns?

A: Yes, the official list of adverse reactions includes Insomnia (trouble sleeping) as a 'very common' side effect reported in clinical trials.

Q: Can Sofgen affect mental clarity or mood?

A: Official product information lists several related effects in the nervous system. Common or very common side effects reported in studies include Headache, Insomnia, Irritability, and Disturbance in attention.

Q: Does Sofgen affect the immune system?

A: Regulatory authorities have issued specific warnings regarding the risk of Hepatitis B Virus (HBV) reactivation. Patients co-infected with HBV and HCV must be screened and monitored, as HBV reactivation can lead to serious liver complications.

Q: Is there a link between Sofgen and liver function issues?

A: Official information mentions that some individuals have experienced increases in Total Bilirubin levels. Additionally, there is a serious warning about the potential for Hepatitis B reactivation in co-infected people, which can cause significant liver problems.

Q: Does taking Sofgen require regular blood tests?

A: Yes, regulatory information indicates that blood tests are typically necessary. These tests are performed to monitor the individual's progress, check for potential unwanted effects, and adjust the dosage of other co-administered medicines, if necessary.

Q: Does Sofgen have a risk of dependence or addiction?

A: The drug is not classified as a controlled substance and official regulatory documents do not indicate a potential for dependence or abuse.

Q: What is the evidence level for Sofgen's effectiveness?

A: The effectiveness is established by evidence derived from high-level clinical studies, primarily Randomized Controlled Trials (RCTs). These trials are classified as Randomized Controlled Trials (RCTs), which provide a high level of evidence for establishing effectiveness.

Q: Are there any long-term research updates about Sofgen?

A: Initial approval was based on fixed-duration trials. However, further specialized research has involved long-term follow-up studies, sometimes extending for several years after treatment ends, to monitor the sustained effects of the viral response and check for long-term safety in specific groups.

Q: What kind of studies were done before Sofgen was approved?

A: The research program included a large number of clinical studies, primarily Randomized Controlled Trials (RCTs). These studies examined the combination regimens across various patient populations and viral types, focusing on achieving a sustained viral response.

How should Sofgen be stored and disposed of?

Official Storage and Disposal Requirements

Official regulatory documentation requires that Sofgen tablets be stored at Controlled Room Temperature, defined as below 30°C (86°F). To maintain product stability, the medicine must be kept in its original container with the lid tightly closed to provide mandatory protection from moisture.

Child Safety

It is a required safety measure to keep Sofgen out of the sight and reach of children; the bottle is supplied with a child-resistant closure to support this instruction.

Disposal

Unused or expired Sofgen must be disposed of according to local regulations. The regulatory label strictly prohibits discarding the medicine via wastewater or household trash. Patients should use an authorized drug take-back program for final disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sofgen found in:

A-Z Index: